Subscribe
Piotr Swat / Shutterstock.com
13 August 2025NewsAmericasMarisa Woutersen

Latham steps into dispute over $6bn treatment, replacing Kirkland

Firm takes over Novartis in major patent litigation | Move follows rival firm's withdrawal after conflict-of-interest challenge | Latham team led by new hire from Cravath.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Biotech seeks to stop Kirkland from representing rival in Eylea dispute
19 June 2025   Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

More on this story

Americas
Biotech seeks to stop Kirkland from representing rival in Eylea dispute
19 June 2025   Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

More on this story

Americas
Biotech seeks to stop Kirkland from representing rival in Eylea dispute
19 June 2025   Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

More features

Weil adds two more litigators from larger rival
Why the PTAB’s new expedited filing dates for AIA petitions is positive
Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Patent pollution: Emissions charter aims to clean up IP
Why Trump’s revenue-raising patent plan is riddled with problems
Harvard’s patent portfolio at risk as Trump turns up the pressure
Weil adds leaders from Latham to head up tech and life sciences
$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech